nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—UGT1A1—Abacavir—acquired immunodeficiency syndrome	0.0687	0.119	CbGbCtD
Nilotinib—ABCG2—Nelfinavir—acquired immunodeficiency syndrome	0.0204	0.0353	CbGbCtD
Nilotinib—CYP2B6—Efavirenz—acquired immunodeficiency syndrome	0.0201	0.0349	CbGbCtD
Nilotinib—CYP2B6—Nevirapine—acquired immunodeficiency syndrome	0.0189	0.0328	CbGbCtD
Nilotinib—CYP2B6—Lopinavir—acquired immunodeficiency syndrome	0.0189	0.0328	CbGbCtD
Nilotinib—ABCG2—Saquinavir—acquired immunodeficiency syndrome	0.0185	0.0319	CbGbCtD
Nilotinib—ABCG2—Ritonavir—acquired immunodeficiency syndrome	0.0185	0.0319	CbGbCtD
Nilotinib—ABCG2—Zidovudine—acquired immunodeficiency syndrome	0.0177	0.0306	CbGbCtD
Nilotinib—CYP2B6—Amprenavir—acquired immunodeficiency syndrome	0.0171	0.0296	CbGbCtD
Nilotinib—CYP2B6—Nelfinavir—acquired immunodeficiency syndrome	0.0144	0.0248	CbGbCtD
Nilotinib—ABCG2—Lamivudine—acquired immunodeficiency syndrome	0.0137	0.0237	CbGbCtD
Nilotinib—CYP2B6—Ritonavir—acquired immunodeficiency syndrome	0.013	0.0225	CbGbCtD
Nilotinib—CYP2C8—Delavirdine—acquired immunodeficiency syndrome	0.013	0.0225	CbGbCtD
Nilotinib—CYP2C8—Amprenavir—acquired immunodeficiency syndrome	0.013	0.0225	CbGbCtD
Nilotinib—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.0106	0.0184	CbGbCtD
Nilotinib—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.01	0.0173	CbGbCtD
Nilotinib—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.01	0.0173	CbGbCtD
Nilotinib—CYP2C8—Saquinavir—acquired immunodeficiency syndrome	0.00983	0.017	CbGbCtD
Nilotinib—CYP2C8—Ritonavir—acquired immunodeficiency syndrome	0.00983	0.017	CbGbCtD
Nilotinib—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.00973	0.0168	CbGbCtD
Nilotinib—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.00971	0.0168	CbGbCtD
Nilotinib—CYP2C8—Zidovudine—acquired immunodeficiency syndrome	0.00943	0.0163	CbGbCtD
Nilotinib—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.00915	0.0158	CbGbCtD
Nilotinib—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.00915	0.0158	CbGbCtD
Nilotinib—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.00905	0.0157	CbGbCtD
Nilotinib—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.00905	0.0157	CbGbCtD
Nilotinib—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.00878	0.0152	CbGbCtD
Nilotinib—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.00828	0.0143	CbGbCtD
Nilotinib—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.00828	0.0143	CbGbCtD
Nilotinib—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.00781	0.0135	CbGbCtD
Nilotinib—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.00758	0.0131	CbGbCtD
Nilotinib—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.00758	0.0131	CbGbCtD
Nilotinib—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.00736	0.0127	CbGbCtD
Nilotinib—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.00714	0.0124	CbGbCtD
Nilotinib—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.00693	0.012	CbGbCtD
Nilotinib—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.00686	0.0119	CbGbCtD
Nilotinib—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.00686	0.0119	CbGbCtD
Nilotinib—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.00666	0.0115	CbGbCtD
Nilotinib—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.00666	0.0115	CbGbCtD
Nilotinib—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.00658	0.0114	CbGbCtD
Nilotinib—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.00638	0.011	CbGbCtD
Nilotinib—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.00627	0.0109	CbGbCtD
Nilotinib—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.00627	0.0109	CbGbCtD
Nilotinib—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.00619	0.0107	CbGbCtD
Nilotinib—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00582	0.0101	CbGbCtD
Nilotinib—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00582	0.0101	CbGbCtD
Nilotinib—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00526	0.00911	CbGbCtD
Nilotinib—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00526	0.00911	CbGbCtD
Nilotinib—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.00494	0.00854	CbGbCtD
Nilotinib—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00454	0.00786	CbGbCtD
Nilotinib—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00441	0.00763	CbGbCtD
Nilotinib—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00399	0.0069	CbGbCtD
Nilotinib—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00399	0.0069	CbGbCtD
Nilotinib—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00382	0.00662	CbGbCtD
Nilotinib—HCK—lung—acquired immunodeficiency syndrome	0.00037	0.00325	CbGeAlD
Nilotinib—FGR—digestive system—acquired immunodeficiency syndrome	0.00037	0.00325	CbGeAlD
Nilotinib—CDC42BPB—lymph node—acquired immunodeficiency syndrome	0.00037	0.00325	CbGeAlD
Nilotinib—ABL2—lung—acquired immunodeficiency syndrome	0.000368	0.00323	CbGeAlD
Nilotinib—CA3—bone marrow—acquired immunodeficiency syndrome	0.000367	0.00322	CbGeAlD
Nilotinib—EPHA3—brain—acquired immunodeficiency syndrome	0.000363	0.00319	CbGeAlD
Nilotinib—EPHB3—central nervous system—acquired immunodeficiency syndrome	0.000359	0.00316	CbGeAlD
Nilotinib—CYP2C8—blood plasma—acquired immunodeficiency syndrome	0.000359	0.00315	CbGeAlD
Nilotinib—EPHA4—vagina—acquired immunodeficiency syndrome	0.000356	0.00313	CbGeAlD
Nilotinib—MAPK14—blood—acquired immunodeficiency syndrome	0.000354	0.00311	CbGeAlD
Nilotinib—LCK—blood—acquired immunodeficiency syndrome	0.000353	0.0031	CbGeAlD
Nilotinib—FGR—blood—acquired immunodeficiency syndrome	0.000353	0.0031	CbGeAlD
Nilotinib—EPHB4—digestive system—acquired immunodeficiency syndrome	0.000352	0.0031	CbGeAlD
Nilotinib—CA3—vagina—acquired immunodeficiency syndrome	0.000352	0.00309	CbGeAlD
Nilotinib—EPHA3—lymph node—acquired immunodeficiency syndrome	0.00035	0.00308	CbGeAlD
Nilotinib—EPHA2—lymphoid tissue—acquired immunodeficiency syndrome	0.00035	0.00307	CbGeAlD
Nilotinib—MAPK8—brain—acquired immunodeficiency syndrome	0.000346	0.00304	CbGeAlD
Nilotinib—EPHA6—brain—acquired immunodeficiency syndrome	0.000346	0.00304	CbGeAlD
Nilotinib—EPHA2—digestive system—acquired immunodeficiency syndrome	0.000346	0.00304	CbGeAlD
Nilotinib—HCK—nervous system—acquired immunodeficiency syndrome	0.000343	0.00301	CbGeAlD
Nilotinib—MAPK14—bone marrow—acquired immunodeficiency syndrome	0.000343	0.00301	CbGeAlD
Nilotinib—TEK—lymphoid tissue—acquired immunodeficiency syndrome	0.000341	0.003	CbGeAlD
Nilotinib—LCK—bone marrow—acquired immunodeficiency syndrome	0.000341	0.003	CbGeAlD
Nilotinib—FGR—bone marrow—acquired immunodeficiency syndrome	0.000341	0.003	CbGeAlD
Nilotinib—MAPK14—spinal cord—acquired immunodeficiency syndrome	0.000341	0.003	CbGeAlD
Nilotinib—EPHA4—lung—acquired immunodeficiency syndrome	0.000337	0.00296	CbGeAlD
Nilotinib—CSF1R—skin of body—acquired immunodeficiency syndrome	0.000336	0.00295	CbGeAlD
Nilotinib—EPHB4—blood—acquired immunodeficiency syndrome	0.000336	0.00295	CbGeAlD
Nilotinib—MAPK8—lymph node—acquired immunodeficiency syndrome	0.000334	0.00294	CbGeAlD
Nilotinib—CA3—lung—acquired immunodeficiency syndrome	0.000333	0.00292	CbGeAlD
Nilotinib—CA14—spinal cord—acquired immunodeficiency syndrome	0.000332	0.00292	CbGeAlD
Nilotinib—HCK—central nervous system—acquired immunodeficiency syndrome	0.00033	0.0029	CbGeAlD
Nilotinib—EPHA2—blood—acquired immunodeficiency syndrome	0.000329	0.00289	CbGeAlD
Nilotinib—MAPK14—vagina—acquired immunodeficiency syndrome	0.000328	0.00288	CbGeAlD
Nilotinib—FGR—vagina—acquired immunodeficiency syndrome	0.000327	0.00287	CbGeAlD
Nilotinib—LCK—vagina—acquired immunodeficiency syndrome	0.000327	0.00287	CbGeAlD
Nilotinib—EPHB4—bone marrow—acquired immunodeficiency syndrome	0.000325	0.00285	CbGeAlD
Nilotinib—EPHB4—spinal cord—acquired immunodeficiency syndrome	0.000323	0.00284	CbGeAlD
Nilotinib—CYP2B6—blood plasma—acquired immunodeficiency syndrome	0.000322	0.00283	CbGeAlD
Nilotinib—TEK—blood—acquired immunodeficiency syndrome	0.000321	0.00282	CbGeAlD
Nilotinib—LYN—brain—acquired immunodeficiency syndrome	0.000319	0.00281	CbGeAlD
Nilotinib—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.000319	0.0028	CbGeAlD
Nilotinib—MAP4K1—brain—acquired immunodeficiency syndrome	0.000314	0.00276	CbGeAlD
Nilotinib—EPHA4—nervous system—acquired immunodeficiency syndrome	0.000312	0.00274	CbGeAlD
Nilotinib—EPHB4—vagina—acquired immunodeficiency syndrome	0.000311	0.00273	CbGeAlD
Nilotinib—MAPK14—lung—acquired immunodeficiency syndrome	0.00031	0.00273	CbGeAlD
Nilotinib—TEK—spinal cord—acquired immunodeficiency syndrome	0.00031	0.00272	CbGeAlD
Nilotinib—PDGFRA—lymphoid tissue—acquired immunodeficiency syndrome	0.000309	0.00272	CbGeAlD
Nilotinib—LCK—lung—acquired immunodeficiency syndrome	0.000309	0.00272	CbGeAlD
Nilotinib—FGR—lung—acquired immunodeficiency syndrome	0.000309	0.00272	CbGeAlD
Nilotinib—CA3—nervous system—acquired immunodeficiency syndrome	0.000308	0.00271	CbGeAlD
Nilotinib—EPHB6—blood—acquired immunodeficiency syndrome	0.000307	0.0027	CbGeAlD
Nilotinib—PDGFRA—digestive system—acquired immunodeficiency syndrome	0.000306	0.00268	CbGeAlD
Nilotinib—KIT—skin of body—acquired immunodeficiency syndrome	0.000305	0.00268	CbGeAlD
Nilotinib—EPHA2—vagina—acquired immunodeficiency syndrome	0.000305	0.00268	CbGeAlD
Nilotinib—MAP4K1—lymph node—acquired immunodeficiency syndrome	0.000304	0.00267	CbGeAlD
Nilotinib—ABL1—retina—acquired immunodeficiency syndrome	0.000303	0.00266	CbGeAlD
Nilotinib—EPHA4—central nervous system—acquired immunodeficiency syndrome	0.0003	0.00264	CbGeAlD
Nilotinib—TIE1—brain—acquired immunodeficiency syndrome	0.0003	0.00264	CbGeAlD
Nilotinib—PDGFRB—skin of body—acquired immunodeficiency syndrome	0.000298	0.00262	CbGeAlD
Nilotinib—CA3—central nervous system—acquired immunodeficiency syndrome	0.000297	0.0026	CbGeAlD
Nilotinib—EPHB6—spinal cord—acquired immunodeficiency syndrome	0.000296	0.0026	CbGeAlD
Nilotinib—EPHB4—lung—acquired immunodeficiency syndrome	0.000294	0.00259	CbGeAlD
Nilotinib—UGT1A1—digestive system—acquired immunodeficiency syndrome	0.000291	0.00256	CbGeAlD
Nilotinib—PDGFRA—blood—acquired immunodeficiency syndrome	0.000291	0.00256	CbGeAlD
Nilotinib—TIE1—lymph node—acquired immunodeficiency syndrome	0.00029	0.00255	CbGeAlD
Nilotinib—EPHA2—lung—acquired immunodeficiency syndrome	0.000289	0.00254	CbGeAlD
Nilotinib—BRAF—brain—acquired immunodeficiency syndrome	0.000288	0.00253	CbGeAlD
Nilotinib—MAPK14—nervous system—acquired immunodeficiency syndrome	0.000287	0.00253	CbGeAlD
Nilotinib—FGR—nervous system—acquired immunodeficiency syndrome	0.000286	0.00252	CbGeAlD
Nilotinib—EPHB3—brain—acquired immunodeficiency syndrome	0.000285	0.00251	CbGeAlD
Nilotinib—EPHB6—vagina—acquired immunodeficiency syndrome	0.000285	0.0025	CbGeAlD
Nilotinib—CA12—digestive system—acquired immunodeficiency syndrome	0.000282	0.00248	CbGeAlD
Nilotinib—TEK—lung—acquired immunodeficiency syndrome	0.000282	0.00247	CbGeAlD
Nilotinib—PDGFRA—spinal cord—acquired immunodeficiency syndrome	0.00028	0.00246	CbGeAlD
Nilotinib—BRAF—lymph node—acquired immunodeficiency syndrome	0.000278	0.00244	CbGeAlD
Nilotinib—UGT1A1—blood—acquired immunodeficiency syndrome	0.000278	0.00244	CbGeAlD
Nilotinib—MAPK14—central nervous system—acquired immunodeficiency syndrome	0.000277	0.00243	CbGeAlD
Nilotinib—EPHB3—lymph node—acquired immunodeficiency syndrome	0.000276	0.00242	CbGeAlD
Nilotinib—FGR—central nervous system—acquired immunodeficiency syndrome	0.000276	0.00242	CbGeAlD
Nilotinib—CSF1R—lymphoid tissue—acquired immunodeficiency syndrome	0.000272	0.00239	CbGeAlD
Nilotinib—PDGFRA—vagina—acquired immunodeficiency syndrome	0.00027	0.00237	CbGeAlD
Nilotinib—EPHB6—lung—acquired immunodeficiency syndrome	0.000269	0.00236	CbGeAlD
Nilotinib—CSF1R—digestive system—acquired immunodeficiency syndrome	0.000269	0.00236	CbGeAlD
Nilotinib—EPHA2—nervous system—acquired immunodeficiency syndrome	0.000267	0.00235	CbGeAlD
Nilotinib—ABL1—skin of body—acquired immunodeficiency syndrome	0.000266	0.00234	CbGeAlD
Nilotinib—MAP2K5—blood—acquired immunodeficiency syndrome	0.000263	0.00231	CbGeAlD
Nilotinib—HCK—brain—acquired immunodeficiency syndrome	0.000262	0.0023	CbGeAlD
Nilotinib—TEK—nervous system—acquired immunodeficiency syndrome	0.000261	0.00229	CbGeAlD
Nilotinib—ABL2—brain—acquired immunodeficiency syndrome	0.000261	0.00229	CbGeAlD
Nilotinib—EPHA2—central nervous system—acquired immunodeficiency syndrome	0.000257	0.00226	CbGeAlD
Nilotinib—CA7—brain—acquired immunodeficiency syndrome	0.000257	0.00225	CbGeAlD
Nilotinib—CSF1R—blood—acquired immunodeficiency syndrome	0.000256	0.00225	CbGeAlD
Nilotinib—PDGFRA—lung—acquired immunodeficiency syndrome	0.000255	0.00224	CbGeAlD
Nilotinib—HCK—lymph node—acquired immunodeficiency syndrome	0.000253	0.00223	CbGeAlD
Nilotinib—MAP2K5—spinal cord—acquired immunodeficiency syndrome	0.000253	0.00222	CbGeAlD
Nilotinib—ABL2—lymph node—acquired immunodeficiency syndrome	0.000252	0.00221	CbGeAlD
Nilotinib—TEK—central nervous system—acquired immunodeficiency syndrome	0.000251	0.00221	CbGeAlD
Nilotinib—EPHB6—nervous system—acquired immunodeficiency syndrome	0.000249	0.00219	CbGeAlD
Nilotinib—CSF1R—bone marrow—acquired immunodeficiency syndrome	0.000248	0.00218	CbGeAlD
Nilotinib—KIT—lymphoid tissue—acquired immunodeficiency syndrome	0.000247	0.00217	CbGeAlD
Nilotinib—CSF1R—spinal cord—acquired immunodeficiency syndrome	0.000247	0.00217	CbGeAlD
Nilotinib—KIT—digestive system—acquired immunodeficiency syndrome	0.000244	0.00215	CbGeAlD
Nilotinib—MAP2K5—vagina—acquired immunodeficiency syndrome	0.000243	0.00214	CbGeAlD
Nilotinib—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000243	0.00213	CbGeAlD
Nilotinib—PDGFRB—lymphoid tissue—acquired immunodeficiency syndrome	0.000242	0.00212	CbGeAlD
Nilotinib—EPHB6—central nervous system—acquired immunodeficiency syndrome	0.00024	0.00211	CbGeAlD
Nilotinib—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000239	0.0021	CbGeAlD
Nilotinib—PDGFRB—digestive system—acquired immunodeficiency syndrome	0.000239	0.0021	CbGeAlD
Nilotinib—EPHA4—brain—acquired immunodeficiency syndrome	0.000238	0.00209	CbGeAlD
Nilotinib—CSF1R—vagina—acquired immunodeficiency syndrome	0.000238	0.00209	CbGeAlD
Nilotinib—PDGFRA—nervous system—acquired immunodeficiency syndrome	0.000236	0.00208	CbGeAlD
Nilotinib—CA12—lung—acquired immunodeficiency syndrome	0.000236	0.00207	CbGeAlD
Nilotinib—CA3—brain—acquired immunodeficiency syndrome	0.000235	0.00207	CbGeAlD
Nilotinib—KIT—blood—acquired immunodeficiency syndrome	0.000233	0.00204	CbGeAlD
Nilotinib—EPHA4—lymph node—acquired immunodeficiency syndrome	0.00023	0.00202	CbGeAlD
Nilotinib—MAP2K5—lung—acquired immunodeficiency syndrome	0.00023	0.00202	CbGeAlD
Nilotinib—PDGFRA—central nervous system—acquired immunodeficiency syndrome	0.000228	0.002	CbGeAlD
Nilotinib—CA3—lymph node—acquired immunodeficiency syndrome	0.000227	0.002	CbGeAlD
Nilotinib—PDGFRB—blood—acquired immunodeficiency syndrome	0.000227	0.002	CbGeAlD
Nilotinib—CA1—lymphoid tissue—acquired immunodeficiency syndrome	0.000226	0.00199	CbGeAlD
Nilotinib—KIT—bone marrow—acquired immunodeficiency syndrome	0.000225	0.00198	CbGeAlD
Nilotinib—CSF1R—lung—acquired immunodeficiency syndrome	0.000225	0.00197	CbGeAlD
Nilotinib—KIT—spinal cord—acquired immunodeficiency syndrome	0.000224	0.00197	CbGeAlD
Nilotinib—CA1—digestive system—acquired immunodeficiency syndrome	0.000223	0.00196	CbGeAlD
Nilotinib—PDGFRB—bone marrow—acquired immunodeficiency syndrome	0.00022	0.00193	CbGeAlD
Nilotinib—MAPK14—brain—acquired immunodeficiency syndrome	0.00022	0.00193	CbGeAlD
Nilotinib—PDGFRB—spinal cord—acquired immunodeficiency syndrome	0.000219	0.00192	CbGeAlD
Nilotinib—FGR—brain—acquired immunodeficiency syndrome	0.000219	0.00192	CbGeAlD
Nilotinib—CA12—nervous system—acquired immunodeficiency syndrome	0.000218	0.00192	CbGeAlD
Nilotinib—KIT—vagina—acquired immunodeficiency syndrome	0.000216	0.00189	CbGeAlD
Nilotinib—ABL1—lymphoid tissue—acquired immunodeficiency syndrome	0.000215	0.00189	CbGeAlD
Nilotinib—CA14—brain—acquired immunodeficiency syndrome	0.000214	0.00188	CbGeAlD
Nilotinib—MAP2K5—nervous system—acquired immunodeficiency syndrome	0.000213	0.00187	CbGeAlD
Nilotinib—CA1—blood—acquired immunodeficiency syndrome	0.000213	0.00187	CbGeAlD
Nilotinib—ABL1—digestive system—acquired immunodeficiency syndrome	0.000213	0.00187	CbGeAlD
Nilotinib—MAPK14—lymph node—acquired immunodeficiency syndrome	0.000212	0.00187	CbGeAlD
Nilotinib—FGR—lymph node—acquired immunodeficiency syndrome	0.000211	0.00186	CbGeAlD
Nilotinib—LCK—lymph node—acquired immunodeficiency syndrome	0.000211	0.00186	CbGeAlD
Nilotinib—PDGFRB—vagina—acquired immunodeficiency syndrome	0.000211	0.00185	CbGeAlD
Nilotinib—CA12—central nervous system—acquired immunodeficiency syndrome	0.00021	0.00184	CbGeAlD
Nilotinib—EPHB4—brain—acquired immunodeficiency syndrome	0.000208	0.00183	CbGeAlD
Nilotinib—CSF1R—nervous system—acquired immunodeficiency syndrome	0.000208	0.00183	CbGeAlD
Nilotinib—CA2—retina—acquired immunodeficiency syndrome	0.000206	0.00181	CbGeAlD
Nilotinib—CA1—bone marrow—acquired immunodeficiency syndrome	0.000206	0.00181	CbGeAlD
Nilotinib—MAP2K5—central nervous system—acquired immunodeficiency syndrome	0.000205	0.0018	CbGeAlD
Nilotinib—CA1—spinal cord—acquired immunodeficiency syndrome	0.000205	0.0018	CbGeAlD
Nilotinib—EPHA2—brain—acquired immunodeficiency syndrome	0.000204	0.0018	CbGeAlD
Nilotinib—KIT—lung—acquired immunodeficiency syndrome	0.000204	0.00179	CbGeAlD
Nilotinib—ABL1—blood—acquired immunodeficiency syndrome	0.000203	0.00178	CbGeAlD
Nilotinib—EPHB4—lymph node—acquired immunodeficiency syndrome	0.000201	0.00177	CbGeAlD
Nilotinib—CSF1R—central nervous system—acquired immunodeficiency syndrome	0.0002	0.00176	CbGeAlD
Nilotinib—TEK—brain—acquired immunodeficiency syndrome	0.000199	0.00175	CbGeAlD
Nilotinib—PDGFRB—lung—acquired immunodeficiency syndrome	0.000199	0.00175	CbGeAlD
Nilotinib—EPHA2—lymph node—acquired immunodeficiency syndrome	0.000197	0.00173	CbGeAlD
Nilotinib—ABL1—bone marrow—acquired immunodeficiency syndrome	0.000196	0.00172	CbGeAlD
Nilotinib—ABL1—spinal cord—acquired immunodeficiency syndrome	0.000195	0.00171	CbGeAlD
Nilotinib—TEK—lymph node—acquired immunodeficiency syndrome	0.000193	0.00169	CbGeAlD
Nilotinib—EPHB6—brain—acquired immunodeficiency syndrome	0.000191	0.00167	CbGeAlD
Nilotinib—KIT—nervous system—acquired immunodeficiency syndrome	0.000189	0.00166	CbGeAlD
Nilotinib—ABL1—vagina—acquired immunodeficiency syndrome	0.000188	0.00165	CbGeAlD
Nilotinib—CA1—lung—acquired immunodeficiency syndrome	0.000187	0.00164	CbGeAlD
Nilotinib—PDGFRB—nervous system—acquired immunodeficiency syndrome	0.000185	0.00162	CbGeAlD
Nilotinib—EPHB6—lymph node—acquired immunodeficiency syndrome	0.000184	0.00162	CbGeAlD
Nilotinib—KIT—central nervous system—acquired immunodeficiency syndrome	0.000182	0.0016	CbGeAlD
Nilotinib—CA2—skin of body—acquired immunodeficiency syndrome	0.000181	0.00159	CbGeAlD
Nilotinib—PDGFRA—brain—acquired immunodeficiency syndrome	0.000181	0.00159	CbGeAlD
Nilotinib—PDGFRB—central nervous system—acquired immunodeficiency syndrome	0.000178	0.00156	CbGeAlD
Nilotinib—ABL1—lung—acquired immunodeficiency syndrome	0.000178	0.00156	CbGeAlD
Nilotinib—CA4—digestive system—acquired immunodeficiency syndrome	0.000175	0.00153	CbGeAlD
Nilotinib—PDGFRA—lymph node—acquired immunodeficiency syndrome	0.000175	0.00153	CbGeAlD
Nilotinib—CA1—nervous system—acquired immunodeficiency syndrome	0.000173	0.00152	CbGeAlD
Nilotinib—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000172	0.00151	CbGeAlD
Nilotinib—CA12—brain—acquired immunodeficiency syndrome	0.000167	0.00146	CbGeAlD
Nilotinib—CA4—blood—acquired immunodeficiency syndrome	0.000166	0.00146	CbGeAlD
Nilotinib—CA1—central nervous system—acquired immunodeficiency syndrome	0.000166	0.00146	CbGeAlD
Nilotinib—ABL1—nervous system—acquired immunodeficiency syndrome	0.000164	0.00144	CbGeAlD
Nilotinib—MAP2K5—brain—acquired immunodeficiency syndrome	0.000163	0.00143	CbGeAlD
Nilotinib—CA4—bone marrow—acquired immunodeficiency syndrome	0.000161	0.00141	CbGeAlD
Nilotinib—CA4—spinal cord—acquired immunodeficiency syndrome	0.00016	0.00141	CbGeAlD
Nilotinib—CSF1R—brain—acquired immunodeficiency syndrome	0.000159	0.0014	CbGeAlD
Nilotinib—ABL1—central nervous system—acquired immunodeficiency syndrome	0.000158	0.00139	CbGeAlD
Nilotinib—MAP2K5—lymph node—acquired immunodeficiency syndrome	0.000157	0.00138	CbGeAlD
Nilotinib—CYP2B6—skin of body—acquired immunodeficiency syndrome	0.000155	0.00136	CbGeAlD
Nilotinib—CSF1R—lymph node—acquired immunodeficiency syndrome	0.000154	0.00135	CbGeAlD
Nilotinib—CA2—lymphoid tissue—acquired immunodeficiency syndrome	0.000147	0.00129	CbGeAlD
Nilotinib—CA4—lung—acquired immunodeficiency syndrome	0.000146	0.00128	CbGeAlD
Nilotinib—CA2—digestive system—acquired immunodeficiency syndrome	0.000145	0.00127	CbGeAlD
Nilotinib—KIT—brain—acquired immunodeficiency syndrome	0.000144	0.00127	CbGeAlD
Nilotinib—PDGFRB—brain—acquired immunodeficiency syndrome	0.000141	0.00124	CbGeAlD
Nilotinib—KIT—lymph node—acquired immunodeficiency syndrome	0.00014	0.00123	CbGeAlD
Nilotinib—CA2—blood—acquired immunodeficiency syndrome	0.000138	0.00121	CbGeAlD
Nilotinib—PDGFRB—lymph node—acquired immunodeficiency syndrome	0.000136	0.0012	CbGeAlD
Nilotinib—CA4—nervous system—acquired immunodeficiency syndrome	0.000135	0.00119	CbGeAlD
Nilotinib—CA2—bone marrow—acquired immunodeficiency syndrome	0.000133	0.00117	CbGeAlD
Nilotinib—CA2—spinal cord—acquired immunodeficiency syndrome	0.000133	0.00117	CbGeAlD
Nilotinib—CA1—brain—acquired immunodeficiency syndrome	0.000132	0.00116	CbGeAlD
Nilotinib—CYP2C8—blood—acquired immunodeficiency syndrome	0.000131	0.00115	CbGeAlD
Nilotinib—CA4—central nervous system—acquired immunodeficiency syndrome	0.00013	0.00114	CbGeAlD
Nilotinib—CA2—vagina—acquired immunodeficiency syndrome	0.000128	0.00112	CbGeAlD
Nilotinib—ABCG2—blood—acquired immunodeficiency syndrome	0.000128	0.00112	CbGeAlD
Nilotinib—CA1—lymph node—acquired immunodeficiency syndrome	0.000128	0.00112	CbGeAlD
Nilotinib—ABL1—brain—acquired immunodeficiency syndrome	0.000126	0.0011	CbGeAlD
Nilotinib—CYP2B6—lymphoid tissue—acquired immunodeficiency syndrome	0.000125	0.0011	CbGeAlD
Nilotinib—CYP2B6—digestive system—acquired immunodeficiency syndrome	0.000124	0.00109	CbGeAlD
Nilotinib—ABCG2—bone marrow—acquired immunodeficiency syndrome	0.000124	0.00109	CbGeAlD
Nilotinib—ABCG2—spinal cord—acquired immunodeficiency syndrome	0.000123	0.00108	CbGeAlD
Nilotinib—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000123	0.00108	CbGeAlD
Nilotinib—CYP2C8—vagina—acquired immunodeficiency syndrome	0.000122	0.00107	CbGeAlD
Nilotinib—ABL1—lymph node—acquired immunodeficiency syndrome	0.000121	0.00107	CbGeAlD
Nilotinib—CA2—lung—acquired immunodeficiency syndrome	0.000121	0.00106	CbGeAlD
Nilotinib—ABCG2—vagina—acquired immunodeficiency syndrome	0.000118	0.00104	CbGeAlD
Nilotinib—CYP2B6—blood—acquired immunodeficiency syndrome	0.000118	0.00104	CbGeAlD
Nilotinib—CYP2C9—blood—acquired immunodeficiency syndrome	0.000117	0.00103	CbGeAlD
Nilotinib—ABCG2—lung—acquired immunodeficiency syndrome	0.000112	0.000984	CbGeAlD
Nilotinib—CA2—nervous system—acquired immunodeficiency syndrome	0.000112	0.000984	CbGeAlD
Nilotinib—Imatinib—ALB—acquired immunodeficiency syndrome	0.000112	1	CrCbGaD
Nilotinib—CYP2B6—vagina—acquired immunodeficiency syndrome	0.000109	0.00096	CbGeAlD
Nilotinib—CA2—central nervous system—acquired immunodeficiency syndrome	0.000108	0.000947	CbGeAlD
Nilotinib—CYP2B6—lung—acquired immunodeficiency syndrome	0.000103	0.000908	CbGeAlD
Nilotinib—CA4—brain—acquired immunodeficiency syndrome	0.000103	0.000907	CbGeAlD
Nilotinib—CA4—lymph node—acquired immunodeficiency syndrome	9.97e-05	0.000876	CbGeAlD
Nilotinib—CYP2B6—nervous system—acquired immunodeficiency syndrome	9.57e-05	0.00084	CbGeAlD
Nilotinib—ABCB1—retina—acquired immunodeficiency syndrome	9.42e-05	0.000827	CbGeAlD
Nilotinib—CYP3A4—digestive system—acquired immunodeficiency syndrome	9.34e-05	0.000821	CbGeAlD
Nilotinib—CYP2B6—central nervous system—acquired immunodeficiency syndrome	9.21e-05	0.000809	CbGeAlD
Nilotinib—CYP2D6—digestive system—acquired immunodeficiency syndrome	9.19e-05	0.000807	CbGeAlD
Nilotinib—CYP3A4—blood—acquired immunodeficiency syndrome	8.9e-05	0.000782	CbGeAlD
Nilotinib—CYP2D6—blood—acquired immunodeficiency syndrome	8.76e-05	0.000769	CbGeAlD
Nilotinib—CA2—brain—acquired immunodeficiency syndrome	8.56e-05	0.000752	CbGeAlD
Nilotinib—CA2—lymph node—acquired immunodeficiency syndrome	8.27e-05	0.000727	CbGeAlD
Nilotinib—CYP2C8—brain—acquired immunodeficiency syndrome	8.15e-05	0.000716	CbGeAlD
Nilotinib—ABCG2—brain—acquired immunodeficiency syndrome	7.93e-05	0.000696	CbGeAlD
Nilotinib—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	7.67e-05	0.000342	CcSEcCtD
Nilotinib—ABCG2—lymph node—acquired immunodeficiency syndrome	7.66e-05	0.000673	CbGeAlD
Nilotinib—Ill-defined disorder—Lamivudine—acquired immunodeficiency syndrome	7.66e-05	0.000342	CcSEcCtD
Nilotinib—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	7.65e-05	0.000341	CcSEcCtD
Nilotinib—Chest pain—Ritonavir—acquired immunodeficiency syndrome	7.65e-05	0.000341	CcSEcCtD
Nilotinib—Myalgia—Ritonavir—acquired immunodeficiency syndrome	7.65e-05	0.000341	CcSEcCtD
Nilotinib—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	7.63e-05	0.00034	CcSEcCtD
Nilotinib—Anaemia—Lamivudine—acquired immunodeficiency syndrome	7.63e-05	0.00034	CcSEcCtD
Nilotinib—Anxiety—Ritonavir—acquired immunodeficiency syndrome	7.62e-05	0.00034	CcSEcCtD
Nilotinib—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	7.6e-05	0.000339	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	7.6e-05	0.000339	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	7.57e-05	0.000338	CcSEcCtD
Nilotinib—Pruritus—Abacavir—acquired immunodeficiency syndrome	7.56e-05	0.000338	CcSEcCtD
Nilotinib—Fatigue—Indinavir—acquired immunodeficiency syndrome	7.56e-05	0.000338	CcSEcCtD
Nilotinib—Anorexia—Delavirdine—acquired immunodeficiency syndrome	7.56e-05	0.000337	CcSEcCtD
Nilotinib—Discomfort—Ritonavir—acquired immunodeficiency syndrome	7.56e-05	0.000337	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	7.55e-05	0.000337	CcSEcCtD
Nilotinib—Cough—Saquinavir—acquired immunodeficiency syndrome	7.55e-05	0.000337	CcSEcCtD
Nilotinib—Constipation—Indinavir—acquired immunodeficiency syndrome	7.5e-05	0.000335	CcSEcCtD
Nilotinib—Pain—Indinavir—acquired immunodeficiency syndrome	7.5e-05	0.000335	CcSEcCtD
Nilotinib—Insomnia—Efavirenz—acquired immunodeficiency syndrome	7.5e-05	0.000335	CcSEcCtD
Nilotinib—Urticaria—Zidovudine—acquired immunodeficiency syndrome	7.49e-05	0.000334	CcSEcCtD
Nilotinib—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	7.48e-05	0.000334	CcSEcCtD
Nilotinib—Hypertension—Saquinavir—acquired immunodeficiency syndrome	7.47e-05	0.000333	CcSEcCtD
Nilotinib—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	7.46e-05	0.000333	CcSEcCtD
Nilotinib—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	7.46e-05	0.000333	CcSEcCtD
Nilotinib—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	7.45e-05	0.000332	CcSEcCtD
Nilotinib—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	7.44e-05	0.000332	CcSEcCtD
Nilotinib—Malaise—Lamivudine—acquired immunodeficiency syndrome	7.44e-05	0.000332	CcSEcCtD
Nilotinib—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	7.43e-05	0.000331	CcSEcCtD
Nilotinib—Nausea—Didanosine—acquired immunodeficiency syndrome	7.43e-05	0.000331	CcSEcCtD
Nilotinib—Vertigo—Lamivudine—acquired immunodeficiency syndrome	7.41e-05	0.000331	CcSEcCtD
Nilotinib—Hypotension—Delavirdine—acquired immunodeficiency syndrome	7.41e-05	0.000331	CcSEcCtD
Nilotinib—Syncope—Lamivudine—acquired immunodeficiency syndrome	7.4e-05	0.00033	CcSEcCtD
Nilotinib—Confusional state—Ritonavir—acquired immunodeficiency syndrome	7.4e-05	0.00033	CcSEcCtD
Nilotinib—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	7.39e-05	0.00033	CcSEcCtD
Nilotinib—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	7.39e-05	0.00033	CcSEcCtD
Nilotinib—Chest pain—Saquinavir—acquired immunodeficiency syndrome	7.36e-05	0.000329	CcSEcCtD
Nilotinib—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	7.36e-05	0.000329	CcSEcCtD
Nilotinib—Myalgia—Saquinavir—acquired immunodeficiency syndrome	7.36e-05	0.000329	CcSEcCtD
Nilotinib—Anxiety—Saquinavir—acquired immunodeficiency syndrome	7.34e-05	0.000328	CcSEcCtD
Nilotinib—Oedema—Ritonavir—acquired immunodeficiency syndrome	7.33e-05	0.000327	CcSEcCtD
Nilotinib—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	7.32e-05	0.000327	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	7.31e-05	0.000326	CcSEcCtD
Nilotinib—CYP2B6—brain—acquired immunodeficiency syndrome	7.31e-05	0.000642	CbGeAlD
Nilotinib—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	7.3e-05	0.000326	CcSEcCtD
Nilotinib—Discomfort—Saquinavir—acquired immunodeficiency syndrome	7.28e-05	0.000325	CcSEcCtD
Nilotinib—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	7.25e-05	0.000324	CcSEcCtD
Nilotinib—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	7.23e-05	0.000323	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	7.23e-05	0.000323	CcSEcCtD
Nilotinib—CYP3A4—nervous system—acquired immunodeficiency syndrome	7.22e-05	0.000635	CbGeAlD
Nilotinib—Shock—Ritonavir—acquired immunodeficiency syndrome	7.22e-05	0.000322	CcSEcCtD
Nilotinib—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	7.21e-05	0.000322	CcSEcCtD
Nilotinib—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	7.2e-05	0.000321	CcSEcCtD
Nilotinib—Cough—Lamivudine—acquired immunodeficiency syndrome	7.2e-05	0.000321	CcSEcCtD
Nilotinib—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	7.2e-05	0.000321	CcSEcCtD
Nilotinib—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	7.19e-05	0.000321	CcSEcCtD
Nilotinib—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	7.18e-05	0.000321	CcSEcCtD
Nilotinib—Dizziness—Stavudine—acquired immunodeficiency syndrome	7.18e-05	0.00032	CcSEcCtD
Nilotinib—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	7.17e-05	0.00032	CcSEcCtD
Nilotinib—Insomnia—Delavirdine—acquired immunodeficiency syndrome	7.17e-05	0.00032	CcSEcCtD
Nilotinib—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	7.16e-05	0.000319	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	7.16e-05	0.000319	CcSEcCtD
Nilotinib—Vomiting—Nevirapine—acquired immunodeficiency syndrome	7.15e-05	0.000319	CcSEcCtD
Nilotinib—Fatigue—Efavirenz—acquired immunodeficiency syndrome	7.15e-05	0.000319	CcSEcCtD
Nilotinib—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	7.12e-05	0.000318	CcSEcCtD
Nilotinib—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	7.12e-05	0.000318	CcSEcCtD
Nilotinib—Confusional state—Saquinavir—acquired immunodeficiency syndrome	7.12e-05	0.000318	CcSEcCtD
Nilotinib—CYP2D6—nervous system—acquired immunodeficiency syndrome	7.11e-05	0.000624	CbGeAlD
Nilotinib—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	7.09e-05	0.000316	CcSEcCtD
Nilotinib—Constipation—Efavirenz—acquired immunodeficiency syndrome	7.09e-05	0.000316	CcSEcCtD
Nilotinib—Pain—Efavirenz—acquired immunodeficiency syndrome	7.09e-05	0.000316	CcSEcCtD
Nilotinib—Rash—Nevirapine—acquired immunodeficiency syndrome	7.09e-05	0.000316	CcSEcCtD
Nilotinib—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	7.08e-05	0.000316	CcSEcCtD
Nilotinib—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	7.07e-05	0.000316	CcSEcCtD
Nilotinib—Dizziness—Abacavir—acquired immunodeficiency syndrome	7.07e-05	0.000316	CcSEcCtD
Nilotinib—Oedema—Saquinavir—acquired immunodeficiency syndrome	7.06e-05	0.000315	CcSEcCtD
Nilotinib—Headache—Nevirapine—acquired immunodeficiency syndrome	7.04e-05	0.000314	CcSEcCtD
Nilotinib—Myalgia—Lamivudine—acquired immunodeficiency syndrome	7.02e-05	0.000314	CcSEcCtD
Nilotinib—Chest pain—Lamivudine—acquired immunodeficiency syndrome	7.02e-05	0.000314	CcSEcCtD
Nilotinib—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	7.02e-05	0.000314	CcSEcCtD
Nilotinib—Infection—Saquinavir—acquired immunodeficiency syndrome	7.01e-05	0.000313	CcSEcCtD
Nilotinib—Anxiety—Lamivudine—acquired immunodeficiency syndrome	7e-05	0.000312	CcSEcCtD
Nilotinib—Anorexia—Ritonavir—acquired immunodeficiency syndrome	6.99e-05	0.000312	CcSEcCtD
Nilotinib—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	6.98e-05	0.000312	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	6.98e-05	0.000311	CcSEcCtD
Nilotinib—Urticaria—Indinavir—acquired immunodeficiency syndrome	6.97e-05	0.000311	CcSEcCtD
Nilotinib—CYP3A4—central nervous system—acquired immunodeficiency syndrome	6.96e-05	0.000611	CbGeAlD
Nilotinib—Shock—Saquinavir—acquired immunodeficiency syndrome	6.94e-05	0.00031	CcSEcCtD
Nilotinib—Discomfort—Lamivudine—acquired immunodeficiency syndrome	6.94e-05	0.00031	CcSEcCtD
Nilotinib—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	6.94e-05	0.00031	CcSEcCtD
Nilotinib—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	6.94e-05	0.00031	CcSEcCtD
Nilotinib—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	6.92e-05	0.000309	CcSEcCtD
Nilotinib—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	6.92e-05	0.000309	CcSEcCtD
Nilotinib—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	6.91e-05	0.000308	CcSEcCtD
Nilotinib—Vomiting—Stavudine—acquired immunodeficiency syndrome	6.9e-05	0.000308	CcSEcCtD
Nilotinib—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	6.89e-05	0.000308	CcSEcCtD
Nilotinib—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	6.87e-05	0.000307	CcSEcCtD
Nilotinib—Rash—Nelfinavir—acquired immunodeficiency syndrome	6.86e-05	0.000306	CcSEcCtD
Nilotinib—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	6.86e-05	0.000306	CcSEcCtD
Nilotinib—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	6.86e-05	0.000306	CcSEcCtD
Nilotinib—Hypotension—Ritonavir—acquired immunodeficiency syndrome	6.85e-05	0.000306	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	6.85e-05	0.000306	CcSEcCtD
Nilotinib—CYP2D6—central nervous system—acquired immunodeficiency syndrome	6.84e-05	0.000601	CbGeAlD
Nilotinib—Rash—Stavudine—acquired immunodeficiency syndrome	6.84e-05	0.000305	CcSEcCtD
Nilotinib—Fatigue—Delavirdine—acquired immunodeficiency syndrome	6.84e-05	0.000305	CcSEcCtD
Nilotinib—Dermatitis—Stavudine—acquired immunodeficiency syndrome	6.84e-05	0.000305	CcSEcCtD
Nilotinib—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	6.83e-05	0.000305	CcSEcCtD
Nilotinib—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	6.82e-05	0.000305	CcSEcCtD
Nilotinib—Headache—Nelfinavir—acquired immunodeficiency syndrome	6.82e-05	0.000304	CcSEcCtD
Nilotinib—Headache—Stavudine—acquired immunodeficiency syndrome	6.8e-05	0.000303	CcSEcCtD
Nilotinib—Vomiting—Abacavir—acquired immunodeficiency syndrome	6.8e-05	0.000303	CcSEcCtD
Nilotinib—Confusional state—Lamivudine—acquired immunodeficiency syndrome	6.79e-05	0.000303	CcSEcCtD
Nilotinib—Constipation—Delavirdine—acquired immunodeficiency syndrome	6.78e-05	0.000303	CcSEcCtD
Nilotinib—Pain—Delavirdine—acquired immunodeficiency syndrome	6.78e-05	0.000303	CcSEcCtD
Nilotinib—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	6.78e-05	0.000303	CcSEcCtD
Nilotinib—Asthenia—Zidovudine—acquired immunodeficiency syndrome	6.77e-05	0.000302	CcSEcCtD
Nilotinib—Rash—Abacavir—acquired immunodeficiency syndrome	6.74e-05	0.000301	CcSEcCtD
Nilotinib—Dermatitis—Abacavir—acquired immunodeficiency syndrome	6.74e-05	0.000301	CcSEcCtD
Nilotinib—Oedema—Lamivudine—acquired immunodeficiency syndrome	6.73e-05	0.000301	CcSEcCtD
Nilotinib—Anorexia—Saquinavir—acquired immunodeficiency syndrome	6.73e-05	0.0003	CcSEcCtD
Nilotinib—Headache—Abacavir—acquired immunodeficiency syndrome	6.7e-05	0.000299	CcSEcCtD
Nilotinib—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	6.69e-05	0.000588	CbGeAlD
Nilotinib—Infection—Lamivudine—acquired immunodeficiency syndrome	6.69e-05	0.000299	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	6.68e-05	0.000298	CcSEcCtD
Nilotinib—Nausea—Nevirapine—acquired immunodeficiency syndrome	6.68e-05	0.000298	CcSEcCtD
Nilotinib—Pruritus—Zidovudine—acquired immunodeficiency syndrome	6.67e-05	0.000298	CcSEcCtD
Nilotinib—Insomnia—Ritonavir—acquired immunodeficiency syndrome	6.63e-05	0.000296	CcSEcCtD
Nilotinib—Shock—Lamivudine—acquired immunodeficiency syndrome	6.63e-05	0.000296	CcSEcCtD
Nilotinib—ABCB1—digestive system—acquired immunodeficiency syndrome	6.61e-05	0.000581	CbGeAlD
Nilotinib—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	6.6e-05	0.000295	CcSEcCtD
Nilotinib—Hypotension—Saquinavir—acquired immunodeficiency syndrome	6.6e-05	0.000294	CcSEcCtD
Nilotinib—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	6.59e-05	0.000294	CcSEcCtD
Nilotinib—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	6.59e-05	0.000294	CcSEcCtD
Nilotinib—Urticaria—Efavirenz—acquired immunodeficiency syndrome	6.58e-05	0.000294	CcSEcCtD
Nilotinib—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	6.55e-05	0.000292	CcSEcCtD
Nilotinib—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	6.55e-05	0.000292	CcSEcCtD
Nilotinib—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	6.54e-05	0.000292	CcSEcCtD
Nilotinib—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	6.54e-05	0.000292	CcSEcCtD
Nilotinib—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	6.54e-05	0.000292	CcSEcCtD
Nilotinib—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	6.51e-05	0.000291	CcSEcCtD
Nilotinib—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	6.49e-05	0.000289	CcSEcCtD
Nilotinib—Nausea—Nelfinavir—acquired immunodeficiency syndrome	6.47e-05	0.000289	CcSEcCtD
Nilotinib—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	6.46e-05	0.000288	CcSEcCtD
Nilotinib—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	6.46e-05	0.000288	CcSEcCtD
Nilotinib—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	6.45e-05	0.000288	CcSEcCtD
Nilotinib—Nausea—Stavudine—acquired immunodeficiency syndrome	6.45e-05	0.000288	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	6.43e-05	0.000287	CcSEcCtD
Nilotinib—Anorexia—Lamivudine—acquired immunodeficiency syndrome	6.42e-05	0.000287	CcSEcCtD
Nilotinib—Insomnia—Saquinavir—acquired immunodeficiency syndrome	6.38e-05	0.000285	CcSEcCtD
Nilotinib—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	6.38e-05	0.000285	CcSEcCtD
Nilotinib—Nausea—Abacavir—acquired immunodeficiency syndrome	6.35e-05	0.000283	CcSEcCtD
Nilotinib—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	6.34e-05	0.000283	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	6.33e-05	0.000283	CcSEcCtD
Nilotinib—Fatigue—Ritonavir—acquired immunodeficiency syndrome	6.32e-05	0.000282	CcSEcCtD
Nilotinib—Urticaria—Delavirdine—acquired immunodeficiency syndrome	6.3e-05	0.000281	CcSEcCtD
Nilotinib—ABCB1—blood—acquired immunodeficiency syndrome	6.3e-05	0.000553	CbGeAlD
Nilotinib—Asthenia—Indinavir—acquired immunodeficiency syndrome	6.29e-05	0.000281	CcSEcCtD
Nilotinib—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	6.29e-05	0.000281	CcSEcCtD
Nilotinib—Hypotension—Lamivudine—acquired immunodeficiency syndrome	6.29e-05	0.000281	CcSEcCtD
Nilotinib—Constipation—Ritonavir—acquired immunodeficiency syndrome	6.27e-05	0.00028	CcSEcCtD
Nilotinib—Pain—Ritonavir—acquired immunodeficiency syndrome	6.27e-05	0.00028	CcSEcCtD
Nilotinib—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	6.27e-05	0.00028	CcSEcCtD
Nilotinib—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	6.27e-05	0.00028	CcSEcCtD
Nilotinib—Dizziness—Zidovudine—acquired immunodeficiency syndrome	6.24e-05	0.000278	CcSEcCtD
Nilotinib—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	6.21e-05	0.000277	CcSEcCtD
Nilotinib—Pruritus—Indinavir—acquired immunodeficiency syndrome	6.21e-05	0.000277	CcSEcCtD
Nilotinib—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	6.14e-05	0.000274	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	6.14e-05	0.000274	CcSEcCtD
Nilotinib—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	6.11e-05	0.000273	CcSEcCtD
Nilotinib—ABCB1—bone marrow—acquired immunodeficiency syndrome	6.1e-05	0.000535	CbGeAlD
Nilotinib—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	6.09e-05	0.000272	CcSEcCtD
Nilotinib—Insomnia—Lamivudine—acquired immunodeficiency syndrome	6.09e-05	0.000272	CcSEcCtD
Nilotinib—Fatigue—Saquinavir—acquired immunodeficiency syndrome	6.09e-05	0.000272	CcSEcCtD
Nilotinib—ABCB1—spinal cord—acquired immunodeficiency syndrome	6.07e-05	0.000533	CbGeAlD
Nilotinib—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	6.05e-05	0.00027	CcSEcCtD
Nilotinib—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	6.04e-05	0.00027	CcSEcCtD
Nilotinib—Constipation—Saquinavir—acquired immunodeficiency syndrome	6.04e-05	0.000269	CcSEcCtD
Nilotinib—Pain—Saquinavir—acquired immunodeficiency syndrome	6.04e-05	0.000269	CcSEcCtD
Nilotinib—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	6e-05	0.000268	CcSEcCtD
Nilotinib—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	6e-05	0.000268	CcSEcCtD
Nilotinib—Vomiting—Zidovudine—acquired immunodeficiency syndrome	6e-05	0.000268	CcSEcCtD
Nilotinib—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	6e-05	0.000268	CcSEcCtD
Nilotinib—Rash—Zidovudine—acquired immunodeficiency syndrome	5.95e-05	0.000265	CcSEcCtD
Nilotinib—Asthenia—Efavirenz—acquired immunodeficiency syndrome	5.95e-05	0.000265	CcSEcCtD
Nilotinib—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	5.94e-05	0.000265	CcSEcCtD
Nilotinib—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	5.93e-05	0.000265	CcSEcCtD
Nilotinib—Headache—Zidovudine—acquired immunodeficiency syndrome	5.91e-05	0.000264	CcSEcCtD
Nilotinib—Pruritus—Efavirenz—acquired immunodeficiency syndrome	5.86e-05	0.000262	CcSEcCtD
Nilotinib—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	5.85e-05	0.000261	CcSEcCtD
Nilotinib—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	5.84e-05	0.000261	CcSEcCtD
Nilotinib—ABCB1—vagina—acquired immunodeficiency syndrome	5.84e-05	0.000513	CbGeAlD
Nilotinib—Urticaria—Ritonavir—acquired immunodeficiency syndrome	5.83e-05	0.00026	CcSEcCtD
Nilotinib—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	5.82e-05	0.00026	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	5.81e-05	0.000259	CcSEcCtD
Nilotinib—Fatigue—Lamivudine—acquired immunodeficiency syndrome	5.81e-05	0.000259	CcSEcCtD
Nilotinib—Dizziness—Indinavir—acquired immunodeficiency syndrome	5.8e-05	0.000259	CcSEcCtD
Nilotinib—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	5.8e-05	0.000259	CcSEcCtD
Nilotinib—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	5.8e-05	0.000259	CcSEcCtD
Nilotinib—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	5.77e-05	0.000258	CcSEcCtD
Nilotinib—Constipation—Lamivudine—acquired immunodeficiency syndrome	5.76e-05	0.000257	CcSEcCtD
Nilotinib—Pain—Lamivudine—acquired immunodeficiency syndrome	5.76e-05	0.000257	CcSEcCtD
Nilotinib—Asthenia—Delavirdine—acquired immunodeficiency syndrome	5.69e-05	0.000254	CcSEcCtD
Nilotinib—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	5.67e-05	0.000253	CcSEcCtD
Nilotinib—Pruritus—Delavirdine—acquired immunodeficiency syndrome	5.61e-05	0.00025	CcSEcCtD
Nilotinib—Urticaria—Saquinavir—acquired immunodeficiency syndrome	5.61e-05	0.00025	CcSEcCtD
Nilotinib—Nausea—Zidovudine—acquired immunodeficiency syndrome	5.6e-05	0.00025	CcSEcCtD
Nilotinib—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	5.58e-05	0.000249	CcSEcCtD
Nilotinib—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	5.58e-05	0.000249	CcSEcCtD
Nilotinib—Vomiting—Indinavir—acquired immunodeficiency syndrome	5.58e-05	0.000249	CcSEcCtD
Nilotinib—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	5.55e-05	0.000248	CcSEcCtD
Nilotinib—Rash—Indinavir—acquired immunodeficiency syndrome	5.53e-05	0.000247	CcSEcCtD
Nilotinib—Dermatitis—Indinavir—acquired immunodeficiency syndrome	5.53e-05	0.000247	CcSEcCtD
Nilotinib—ABCB1—lung—acquired immunodeficiency syndrome	5.52e-05	0.000485	CbGeAlD
Nilotinib—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	5.51e-05	0.000246	CcSEcCtD
Nilotinib—Headache—Indinavir—acquired immunodeficiency syndrome	5.5e-05	0.000245	CcSEcCtD
Nilotinib—Dizziness—Efavirenz—acquired immunodeficiency syndrome	5.48e-05	0.000245	CcSEcCtD
Nilotinib—CYP2D6—brain—acquired immunodeficiency syndrome	5.43e-05	0.000477	CbGeAlD
Nilotinib—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	5.43e-05	0.000242	CcSEcCtD
Nilotinib—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	5.4e-05	0.000241	CcSEcCtD
Nilotinib—Urticaria—Lamivudine—acquired immunodeficiency syndrome	5.35e-05	0.000239	CcSEcCtD
Nilotinib—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	5.32e-05	0.000238	CcSEcCtD
Nilotinib—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	5.32e-05	0.000238	CcSEcCtD
Nilotinib—Vomiting—Efavirenz—acquired immunodeficiency syndrome	5.27e-05	0.000235	CcSEcCtD
Nilotinib—Asthenia—Ritonavir—acquired immunodeficiency syndrome	5.26e-05	0.000235	CcSEcCtD
Nilotinib—Dizziness—Delavirdine—acquired immunodeficiency syndrome	5.24e-05	0.000234	CcSEcCtD
Nilotinib—Rash—Efavirenz—acquired immunodeficiency syndrome	5.23e-05	0.000233	CcSEcCtD
Nilotinib—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	5.22e-05	0.000233	CcSEcCtD
Nilotinib—Nausea—Indinavir—acquired immunodeficiency syndrome	5.21e-05	0.000233	CcSEcCtD
Nilotinib—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	5.2e-05	0.000232	CcSEcCtD
Nilotinib—Headache—Efavirenz—acquired immunodeficiency syndrome	5.19e-05	0.000232	CcSEcCtD
Nilotinib—Pruritus—Ritonavir—acquired immunodeficiency syndrome	5.19e-05	0.000232	CcSEcCtD
Nilotinib—ABCB1—nervous system—acquired immunodeficiency syndrome	5.11e-05	0.000449	CbGeAlD
Nilotinib—Asthenia—Saquinavir—acquired immunodeficiency syndrome	5.06e-05	0.000226	CcSEcCtD
Nilotinib—Vomiting—Delavirdine—acquired immunodeficiency syndrome	5.04e-05	0.000225	CcSEcCtD
Nilotinib—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	5.02e-05	0.000224	CcSEcCtD
Nilotinib—Rash—Delavirdine—acquired immunodeficiency syndrome	5e-05	0.000223	CcSEcCtD
Nilotinib—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	5e-05	0.000223	CcSEcCtD
Nilotinib—Pruritus—Saquinavir—acquired immunodeficiency syndrome	4.99e-05	0.000223	CcSEcCtD
Nilotinib—Headache—Delavirdine—acquired immunodeficiency syndrome	4.97e-05	0.000222	CcSEcCtD
Nilotinib—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	4.96e-05	0.000221	CcSEcCtD
Nilotinib—Nausea—Efavirenz—acquired immunodeficiency syndrome	4.92e-05	0.00022	CcSEcCtD
Nilotinib—ABCB1—central nervous system—acquired immunodeficiency syndrome	4.92e-05	0.000432	CbGeAlD
Nilotinib—Dizziness—Ritonavir—acquired immunodeficiency syndrome	4.85e-05	0.000216	CcSEcCtD
Nilotinib—Asthenia—Lamivudine—acquired immunodeficiency syndrome	4.83e-05	0.000216	CcSEcCtD
Nilotinib—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	4.83e-05	0.000216	CcSEcCtD
Nilotinib—Pruritus—Lamivudine—acquired immunodeficiency syndrome	4.76e-05	0.000213	CcSEcCtD
Nilotinib—Nausea—Delavirdine—acquired immunodeficiency syndrome	4.71e-05	0.00021	CcSEcCtD
Nilotinib—Dizziness—Saquinavir—acquired immunodeficiency syndrome	4.67e-05	0.000208	CcSEcCtD
Nilotinib—Vomiting—Ritonavir—acquired immunodeficiency syndrome	4.66e-05	0.000208	CcSEcCtD
Nilotinib—Rash—Ritonavir—acquired immunodeficiency syndrome	4.62e-05	0.000206	CcSEcCtD
Nilotinib—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	4.62e-05	0.000206	CcSEcCtD
Nilotinib—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	4.61e-05	0.000206	CcSEcCtD
Nilotinib—Headache—Ritonavir—acquired immunodeficiency syndrome	4.59e-05	0.000205	CcSEcCtD
Nilotinib—Vomiting—Saquinavir—acquired immunodeficiency syndrome	4.49e-05	0.0002	CcSEcCtD
Nilotinib—Dizziness—Lamivudine—acquired immunodeficiency syndrome	4.45e-05	0.000199	CcSEcCtD
Nilotinib—Rash—Saquinavir—acquired immunodeficiency syndrome	4.45e-05	0.000199	CcSEcCtD
Nilotinib—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	4.45e-05	0.000198	CcSEcCtD
Nilotinib—Headache—Saquinavir—acquired immunodeficiency syndrome	4.42e-05	0.000197	CcSEcCtD
Nilotinib—Nausea—Ritonavir—acquired immunodeficiency syndrome	4.36e-05	0.000194	CcSEcCtD
Nilotinib—Vomiting—Lamivudine—acquired immunodeficiency syndrome	4.28e-05	0.000191	CcSEcCtD
Nilotinib—Rash—Lamivudine—acquired immunodeficiency syndrome	4.25e-05	0.00019	CcSEcCtD
Nilotinib—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	4.24e-05	0.000189	CcSEcCtD
Nilotinib—Headache—Lamivudine—acquired immunodeficiency syndrome	4.22e-05	0.000188	CcSEcCtD
Nilotinib—Nausea—Saquinavir—acquired immunodeficiency syndrome	4.19e-05	0.000187	CcSEcCtD
Nilotinib—Nausea—Lamivudine—acquired immunodeficiency syndrome	4e-05	0.000179	CcSEcCtD
Nilotinib—ABCB1—brain—acquired immunodeficiency syndrome	3.91e-05	0.000343	CbGeAlD
Nilotinib—ABCB1—lymph node—acquired immunodeficiency syndrome	3.78e-05	0.000332	CbGeAlD
Nilotinib—MAPK14—Hemostasis—ALB—acquired immunodeficiency syndrome	1.62e-05	0.000192	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CD79A—acquired immunodeficiency syndrome	1.61e-05	0.000192	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	1.6e-05	0.000191	CbGpPWpGaD
Nilotinib—LCK—Immune System—CCR2—acquired immunodeficiency syndrome	1.6e-05	0.00019	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	1.59e-05	0.000189	CbGpPWpGaD
Nilotinib—MAPK14—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	1.58e-05	0.000188	CbGpPWpGaD
Nilotinib—KIT—Immune System—HLA-B—acquired immunodeficiency syndrome	1.58e-05	0.000188	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.58e-05	0.000188	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CD40LG—acquired immunodeficiency syndrome	1.57e-05	0.000187	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.57e-05	0.000187	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.57e-05	0.000187	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.56e-05	0.000185	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.56e-05	0.000185	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.56e-05	0.000185	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CD8A—acquired immunodeficiency syndrome	1.56e-05	0.000185	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CSF2—acquired immunodeficiency syndrome	1.56e-05	0.000185	CbGpPWpGaD
Nilotinib—LCK—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	1.54e-05	0.000183	CbGpPWpGaD
Nilotinib—LCK—DAP12 interactions—IL6—acquired immunodeficiency syndrome	1.54e-05	0.000183	CbGpPWpGaD
Nilotinib—LCK—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	1.54e-05	0.000183	CbGpPWpGaD
Nilotinib—KIT—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.54e-05	0.000183	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.53e-05	0.000182	CbGpPWpGaD
Nilotinib—LCK—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	1.53e-05	0.000182	CbGpPWpGaD
Nilotinib—BRAF—Disease—CCR5—acquired immunodeficiency syndrome	1.52e-05	0.000181	CbGpPWpGaD
Nilotinib—LCK—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	1.52e-05	0.00018	CbGpPWpGaD
Nilotinib—LCK—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	1.51e-05	0.000179	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.51e-05	0.000179	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.5e-05	0.000178	CbGpPWpGaD
Nilotinib—HCK—Immune System—IFNG—acquired immunodeficiency syndrome	1.5e-05	0.000178	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—HLA-B—acquired immunodeficiency syndrome	1.5e-05	0.000178	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.48e-05	0.000176	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.47e-05	0.000175	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.45e-05	0.000173	CbGpPWpGaD
Nilotinib—HCK—Immune System—CD4—acquired immunodeficiency syndrome	1.45e-05	0.000172	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	1.45e-05	0.000172	CbGpPWpGaD
Nilotinib—LCK—Immune System—IFNA1—acquired immunodeficiency syndrome	1.44e-05	0.000171	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.43e-05	0.00017	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.43e-05	0.00017	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.42e-05	0.000169	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.42e-05	0.000168	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.42e-05	0.000168	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CD40LG—acquired immunodeficiency syndrome	1.42e-05	0.000168	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.41e-05	0.000167	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CD8A—acquired immunodeficiency syndrome	1.4e-05	0.000167	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CSF2—acquired immunodeficiency syndrome	1.4e-05	0.000167	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—ALB—acquired immunodeficiency syndrome	1.4e-05	0.000166	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD79A—acquired immunodeficiency syndrome	1.39e-05	0.000166	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.39e-05	0.000165	CbGpPWpGaD
Nilotinib—KIT—Disease—CCR5—acquired immunodeficiency syndrome	1.39e-05	0.000165	CbGpPWpGaD
Nilotinib—LYN—Immune System—CD40LG—acquired immunodeficiency syndrome	1.39e-05	0.000165	CbGpPWpGaD
Nilotinib—LCK—Disease—CXCR4—acquired immunodeficiency syndrome	1.39e-05	0.000165	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—IL2—acquired immunodeficiency syndrome	1.38e-05	0.000164	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.38e-05	0.000164	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CD40LG—acquired immunodeficiency syndrome	1.38e-05	0.000164	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—IL2—acquired immunodeficiency syndrome	1.38e-05	0.000164	CbGpPWpGaD
Nilotinib—LYN—Immune System—CSF2—acquired immunodeficiency syndrome	1.37e-05	0.000163	CbGpPWpGaD
Nilotinib—LYN—Immune System—CD8A—acquired immunodeficiency syndrome	1.37e-05	0.000163	CbGpPWpGaD
Nilotinib—LCK—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	1.37e-05	0.000162	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CD8A—acquired immunodeficiency syndrome	1.37e-05	0.000162	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CSF2—acquired immunodeficiency syndrome	1.37e-05	0.000162	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	1.36e-05	0.000162	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—TNF—acquired immunodeficiency syndrome	1.36e-05	0.000162	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—IFNG—acquired immunodeficiency syndrome	1.36e-05	0.000162	CbGpPWpGaD
Nilotinib—BLK—Immune System—IFNG—acquired immunodeficiency syndrome	1.36e-05	0.000162	CbGpPWpGaD
Nilotinib—FGR—Immune System—IFNG—acquired immunodeficiency syndrome	1.36e-05	0.000161	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.35e-05	0.000161	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.35e-05	0.000161	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	1.35e-05	0.000161	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—HLA-B—acquired immunodeficiency syndrome	1.35e-05	0.00016	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.35e-05	0.00016	CbGpPWpGaD
Nilotinib—HCK—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.35e-05	0.00016	CbGpPWpGaD
Nilotinib—CA4—Metabolism—ALB—acquired immunodeficiency syndrome	1.34e-05	0.00016	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.34e-05	0.000159	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.34e-05	0.000159	CbGpPWpGaD
Nilotinib—HCK—Disease—CD4—acquired immunodeficiency syndrome	1.34e-05	0.000159	CbGpPWpGaD
Nilotinib—HCK—Immune System—IL2—acquired immunodeficiency syndrome	1.33e-05	0.000159	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.33e-05	0.000158	CbGpPWpGaD
Nilotinib—LYN—Immune System—HLA-B—acquired immunodeficiency syndrome	1.32e-05	0.000157	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.32e-05	0.000157	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CD40LG—acquired immunodeficiency syndrome	1.32e-05	0.000156	CbGpPWpGaD
Nilotinib—BLK—Immune System—CD4—acquired immunodeficiency syndrome	1.31e-05	0.000156	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—CD4—acquired immunodeficiency syndrome	1.31e-05	0.000156	CbGpPWpGaD
Nilotinib—ABL1—Immune System—HLA-B—acquired immunodeficiency syndrome	1.31e-05	0.000156	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—CCR5—acquired immunodeficiency syndrome	1.31e-05	0.000156	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—IL2—acquired immunodeficiency syndrome	1.31e-05	0.000156	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.31e-05	0.000156	CbGpPWpGaD
Nilotinib—FGR—Immune System—CD4—acquired immunodeficiency syndrome	1.31e-05	0.000156	CbGpPWpGaD
Nilotinib—LYN—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	1.3e-05	0.000155	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CD8A—acquired immunodeficiency syndrome	1.3e-05	0.000155	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CSF2—acquired immunodeficiency syndrome	1.3e-05	0.000155	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.3e-05	0.000154	CbGpPWpGaD
Nilotinib—MAPK14—Cellular responses to stress—IL6—acquired immunodeficiency syndrome	1.3e-05	0.000154	CbGpPWpGaD
Nilotinib—CA2—Metabolism—ALB—acquired immunodeficiency syndrome	1.29e-05	0.000153	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.29e-05	0.000153	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.29e-05	0.000153	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.28e-05	0.000152	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.26e-05	0.00015	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—HLA-B—acquired immunodeficiency syndrome	1.25e-05	0.000149	CbGpPWpGaD
Nilotinib—CA1—Metabolism—ALB—acquired immunodeficiency syndrome	1.24e-05	0.000147	CbGpPWpGaD
Nilotinib—MAPK8—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.22e-05	0.000145	CbGpPWpGaD
Nilotinib—MAPK14—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.22e-05	0.000145	CbGpPWpGaD
Nilotinib—FGR—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.22e-05	0.000144	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.21e-05	0.000144	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.21e-05	0.000144	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—IL2—acquired immunodeficiency syndrome	1.21e-05	0.000144	CbGpPWpGaD
Nilotinib—BLK—Immune System—IL2—acquired immunodeficiency syndrome	1.21e-05	0.000144	CbGpPWpGaD
Nilotinib—FGR—Immune System—IL2—acquired immunodeficiency syndrome	1.2e-05	0.000143	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.2e-05	0.000142	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.19e-05	0.000142	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.18e-05	0.000141	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.18e-05	0.000141	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.18e-05	0.000141	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CCR5—acquired immunodeficiency syndrome	1.18e-05	0.000141	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.18e-05	0.00014	CbGpPWpGaD
Nilotinib—ABCG2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.17e-05	0.000139	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.17e-05	0.000139	CbGpPWpGaD
Nilotinib—LYN—Axon guidance—IL6—acquired immunodeficiency syndrome	1.16e-05	0.000138	CbGpPWpGaD
Nilotinib—ABL1—Axon guidance—IL6—acquired immunodeficiency syndrome	1.16e-05	0.000137	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.14e-05	0.000136	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD40LG—acquired immunodeficiency syndrome	1.14e-05	0.000135	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—IL2—acquired immunodeficiency syndrome	1.13e-05	0.000135	CbGpPWpGaD
Nilotinib—LCK—Immune System—CSF2—acquired immunodeficiency syndrome	1.12e-05	0.000134	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD8A—acquired immunodeficiency syndrome	1.12e-05	0.000134	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.12e-05	0.000133	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.12e-05	0.000133	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.11e-05	0.000132	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.1e-05	0.000131	CbGpPWpGaD
Nilotinib—CA9—Metabolism—ALB—acquired immunodeficiency syndrome	1.09e-05	0.000129	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IFNG—acquired immunodeficiency syndrome	1.08e-05	0.000129	CbGpPWpGaD
Nilotinib—LCK—Immune System—HLA-B—acquired immunodeficiency syndrome	1.08e-05	0.000129	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.08e-05	0.000128	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.08e-05	0.000128	CbGpPWpGaD
Nilotinib—LCK—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	1.07e-05	0.000127	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.07e-05	0.000127	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.06e-05	0.000127	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.06e-05	0.000126	CbGpPWpGaD
Nilotinib—LCK—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.05e-05	0.000125	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	1.05e-05	0.000125	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—CD4—acquired immunodeficiency syndrome	1.05e-05	0.000124	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.03e-05	0.000123	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—TNF—acquired immunodeficiency syndrome	1.03e-05	0.000122	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—TNF—acquired immunodeficiency syndrome	1.02e-05	0.000121	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.02e-05	0.000121	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.01e-05	0.000119	CbGpPWpGaD
Nilotinib—KIT—Immune System—IFNG—acquired immunodeficiency syndrome	9.77e-06	0.000116	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—TNF—acquired immunodeficiency syndrome	9.73e-06	0.000116	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—IL6—acquired immunodeficiency syndrome	9.72e-06	0.000115	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.72e-06	0.000115	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	9.7e-06	0.000115	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	9.7e-06	0.000115	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IL2—acquired immunodeficiency syndrome	9.63e-06	0.000114	CbGpPWpGaD
Nilotinib—BRAF—Disease—CD4—acquired immunodeficiency syndrome	9.57e-06	0.000114	CbGpPWpGaD
Nilotinib—LCK—Disease—CCR5—acquired immunodeficiency syndrome	9.5e-06	0.000113	CbGpPWpGaD
Nilotinib—KIT—Immune System—CD4—acquired immunodeficiency syndrome	9.44e-06	0.000112	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	9.43e-06	0.000112	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IFNG—acquired immunodeficiency syndrome	9.25e-06	0.00011	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.2e-06	0.000109	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.2e-06	0.000109	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.06e-06	0.000108	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9e-06	0.000107	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CD4—acquired immunodeficiency syndrome	8.93e-06	0.000106	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	8.92e-06	0.000106	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.87e-06	0.000105	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—IL6—acquired immunodeficiency syndrome	8.76e-06	0.000104	CbGpPWpGaD
Nilotinib—KIT—Disease—CD4—acquired immunodeficiency syndrome	8.71e-06	0.000104	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL2—acquired immunodeficiency syndrome	8.68e-06	0.000103	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.54e-06	0.000101	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.41e-06	9.99e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IFNG—acquired immunodeficiency syndrome	8.33e-06	9.9e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—IL6—acquired immunodeficiency syndrome	8.29e-06	9.86e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.29e-06	9.85e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—IL6—acquired immunodeficiency syndrome	8.28e-06	9.84e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—CD4—acquired immunodeficiency syndrome	8.25e-06	9.8e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—IL6—acquired immunodeficiency syndrome	8.25e-06	9.8e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL2—acquired immunodeficiency syndrome	8.22e-06	9.77e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IFNG—acquired immunodeficiency syndrome	8.16e-06	9.69e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IFNG—acquired immunodeficiency syndrome	8.12e-06	9.65e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.11e-06	9.64e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CD4—acquired immunodeficiency syndrome	8.05e-06	9.56e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—CD4—acquired immunodeficiency syndrome	7.88e-06	9.36e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—IL6—acquired immunodeficiency syndrome	7.85e-06	9.33e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CD4—acquired immunodeficiency syndrome	7.84e-06	9.32e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—IL6—acquired immunodeficiency syndrome	7.84e-06	9.32e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.81e-06	9.29e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IFNG—acquired immunodeficiency syndrome	7.73e-06	9.19e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.69e-06	9.14e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	7.65e-06	9.09e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—IL6—acquired immunodeficiency syndrome	7.47e-06	8.88e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CD4—acquired immunodeficiency syndrome	7.47e-06	8.88e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CD4—acquired immunodeficiency syndrome	7.43e-06	8.83e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.43e-06	8.83e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL2—acquired immunodeficiency syndrome	7.4e-06	8.8e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.38e-06	8.77e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—IL6—acquired immunodeficiency syndrome	7.32e-06	8.69e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—IL6—acquired immunodeficiency syndrome	7.28e-06	8.65e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.27e-06	8.64e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL2—acquired immunodeficiency syndrome	7.25e-06	8.62e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—IL6—acquired immunodeficiency syndrome	7.24e-06	8.6e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL2—acquired immunodeficiency syndrome	7.22e-06	8.58e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—IL6—acquired immunodeficiency syndrome	7.1e-06	8.44e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—IL6—acquired immunodeficiency syndrome	7.1e-06	8.44e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—IL6—acquired immunodeficiency syndrome	7.08e-06	8.41e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—IL6—acquired immunodeficiency syndrome	6.94e-06	8.24e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL2—acquired immunodeficiency syndrome	6.87e-06	8.17e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IFNG—acquired immunodeficiency syndrome	6.69e-06	7.95e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.65e-06	7.9e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—ALB—acquired immunodeficiency syndrome	6.47e-06	7.69e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD4—acquired immunodeficiency syndrome	6.46e-06	7.67e-05	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	6.34e-06	7.53e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.23e-06	7.4e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	6.23e-06	7.4e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.17e-06	7.33e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—IL6—acquired immunodeficiency syndrome	6e-06	7.13e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CD4—acquired immunodeficiency syndrome	5.96e-06	7.09e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL2—acquired immunodeficiency syndrome	5.94e-06	7.06e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IL6—acquired immunodeficiency syndrome	5.66e-06	6.73e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.61e-06	6.67e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—ALB—acquired immunodeficiency syndrome	5.49e-06	6.52e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.31e-06	6.31e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—IL6—acquired immunodeficiency syndrome	5.18e-06	6.15e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL6—acquired immunodeficiency syndrome	5.1e-06	6.06e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL6—acquired immunodeficiency syndrome	4.83e-06	5.74e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.79e-06	5.69e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—IL6—acquired immunodeficiency syndrome	4.71e-06	5.6e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.69e-06	5.57e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.59e-06	5.46e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—IL6—acquired immunodeficiency syndrome	4.46e-06	5.3e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.44e-06	5.28e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.37e-06	5.19e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL6—acquired immunodeficiency syndrome	4.35e-06	5.17e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL6—acquired immunodeficiency syndrome	4.26e-06	5.06e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL6—acquired immunodeficiency syndrome	4.24e-06	5.04e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL6—acquired immunodeficiency syndrome	4.04e-06	4.8e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ALB—acquired immunodeficiency syndrome	4.02e-06	4.78e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—IL6—acquired immunodeficiency syndrome	4.02e-06	4.78e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.84e-06	4.57e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.66e-06	4.35e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.63e-06	4.31e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL6—acquired immunodeficiency syndrome	3.49e-06	4.15e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ALB—acquired immunodeficiency syndrome	3.41e-06	4.05e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.3e-06	3.92e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—IL6—acquired immunodeficiency syndrome	3.22e-06	3.83e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.12e-06	3.71e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	2.97e-06	3.53e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.81e-06	3.34e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	2.8e-06	3.32e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	2.77e-06	3.29e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.75e-06	3.27e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.61e-06	3.1e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.26e-06	2.68e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	1.83e-06	2.17e-05	CbGpPWpGaD
